While the promising results of several preclinical studies provide a rationale for further investigating the combination of clinically established treatment options such as genotoxic chemotherapy with MDM2 inhibitors in GBM patients, there are also limitations to such combinatorial approaches. The gene discussed is MDM2; the disease is glioblastoma.